De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Joincare Pharmaceutical Group IndustryLtd Beheer
Beheer criteriumcontroles 1/4
Momenteel beschikken wij niet over voldoende informatie over de CEO.
Belangrijke informatie
Xiong Yu
Algemeen directeur
CN¥3.6m
Totale compensatie
| Percentage CEO-salaris | 72.2% |
| Dienstverband CEO | no data |
| Eigendom CEO | n/a |
| Management gemiddelde ambtstermijn | geen gegevens |
| Gemiddelde ambtstermijn bestuur | geen gegevens |
Recente managementupdates
Recent updates
Joincare Pharmaceutical Group Industry Co.,Ltd.'s (SHSE:600380) Business And Shares Still Trailing The Market
Aug 13
We Think Joincare Pharmaceutical Group IndustryLtd (SHSE:600380) Can Manage Its Debt With Ease
Jun 23Shareholders Will Probably Hold Off On Increasing Joincare Pharmaceutical Group Industry Co.,Ltd.'s (SHSE:600380) CEO Compensation For The Time Being
May 31Joincare Pharmaceutical Group IndustryLtd's (SHSE:600380) Conservative Accounting Might Explain Soft Earnings
Apr 09Investors Don't See Light At End Of Joincare Pharmaceutical Group Industry Co.,Ltd.'s (SHSE:600380) Tunnel
Mar 04Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | CN¥1b |
| Mar 31 2024 | n/a | n/a | CN¥1b |
| Dec 31 2023 | CN¥4m | CN¥3m | CN¥1b |
| Sep 30 2023 | n/a | n/a | CN¥1b |
| Jun 30 2023 | n/a | n/a | CN¥2b |
| Mar 31 2023 | n/a | n/a | CN¥2b |
| Dec 31 2022 | CN¥4m | CN¥3m | CN¥2b |
| Sep 30 2022 | n/a | n/a | CN¥1b |
| Jun 30 2022 | n/a | n/a | CN¥1b |
| Mar 31 2022 | n/a | n/a | CN¥1b |
| Dec 31 2021 | CN¥3m | CN¥2m | CN¥1b |
Compensatie versus markt: De totale vergoeding ($USD 512.92K ) Xiong } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de CN markt ($USD 214.50K ).
Compensatie versus inkomsten: De vergoeding van Xiong is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Xiong Yu (63 yo)
no data
Tenure
CN¥3,600,000
Compensatie
Mr. Xiong Yu serves as Non-Executive Director of Livzon Pharmaceutical Group Inc. since June 30, 2020. He serves as the Deputy Vice-President and a Researcher of China State Institute of Pharmaceutical Ind...